Analysts Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $9.31

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have received an average rating of “Buy” from the ten analysts that are presently covering the firm, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $9.31.

Several research firms have recently issued reports on TRVI. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Leerink Partners began coverage on shares of Trevi Therapeutics in a research note on Monday, September 9th. They issued an “outperform” rating and a $7.00 target price on the stock. B. Riley reissued a “buy” rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a research note on Monday, October 7th. HC Wainwright lifted their target price on Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research report on Thursday, December 12th. Finally, Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Trevi Therapeutics in a research report on Thursday, December 12th.

Trevi Therapeutics Stock Performance

Shares of TRVI opened at $4.59 on Thursday. The business has a 50-day moving average of $3.31 and a 200 day moving average of $3.09. The firm has a market cap of $352.81 million, a P/E ratio of -10.43 and a beta of 0.96. Trevi Therapeutics has a fifty-two week low of $1.27 and a fifty-two week high of $4.68.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same quarter last year, the firm posted ($0.08) earnings per share. As a group, research analysts predict that Trevi Therapeutics will post -0.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets boosted its position in Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock valued at $40,000 after buying an additional 6,764 shares during the last quarter. Hsbc Holdings PLC purchased a new position in shares of Trevi Therapeutics during the second quarter worth $61,000. Intech Investment Management LLC purchased a new stake in Trevi Therapeutics in the third quarter valued at $63,000. The Manufacturers Life Insurance Company grew its position in Trevi Therapeutics by 87.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,524 shares of the company’s stock worth $73,000 after purchasing an additional 11,450 shares during the period. Finally, SG Americas Securities LLC purchased a new position in shares of Trevi Therapeutics during the 3rd quarter valued at about $78,000. 95.76% of the stock is currently owned by institutional investors and hedge funds.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.